ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Host immune dysfunction and Mycoplasma pneumoniae immune evasion: dual drivers of pathogenesis in Mycoplasma pneumoniae pneumonia.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-Omics Profiling Identifies Immune-Metabolic Signatures and Gut Microbial Biomarkers in a Murine Model ofBiology · 2026Article
- Research progress and trends of Mycoplasma pneumoniae pneumonia in children: a bibliometric and visualization analysis (1990s to post-COVID-19 era).Pediatric research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae pneumonia (MPP) is a highly prevalent form of community-acquired pneumonia (CAP) that can be complicated by severe extrapulmonary manifestations, leading to poor prognosis. The immunopathogenesis of MPP remains incompletely elucidated. This review synthesizes recent advancements, identifying host immune dysfunction and microbial immune evasion as the pivotal dual drivers of MPP immunopathogenesis. We detail how dysregulation of both innate and adaptive immunity—including impaired macrophage function, neutrophil-driven hyperinflammation, paradoxical natural killer (NK) cell activity, and imbalances in T-cell subsets—leads to ineffective pathogen clearance and promotes tissue damage. Concurrently, Mycoplasma pneumoniae perpetuates infection through strategies such as antigenic variation, the expression of an immunoglobulin-binding protein of Mycoplasma (IbpM), and intracellular invasion. Furthermore, we explore the role of autoimmune mechanisms, including molecular mimicry, in mediating extrapulmonary complications. Finally, we highlight the importance of translating these mechanistic insights into targeted immunotherapies and rational vaccine design, which are essential for overcoming current therapeutic limitations and improving clinical outcomes for patients with MPP.
Indexed as
Identifiers
41774154What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.